Quick Answer
Dyne Therapeutics, Inc. reported Research And Development Expense of $398.33 million for the year ending 2025.
- Dyne Therapeutics, Inc. showed an increase of +41.6% in Research And Development Expense from 2024 to 2025.
- This data is from Dyne Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: $2.98 million | Q1 2020: $6.09 million | Q2 2020: $7.33 million | Q3 2020: $9.68 million | Q1 2021: $18.63 million | Q2 2021: $23.87 million | Q3 2021: $36.51 million | Q1 2022: $28.24 million | Q2 2022: $46.66 million | Q3 2022: $34.67 million | Q1 2023: $37.54 million | Q2 2023: $59.13 million | Q3 2023: $55.25 million | Q1 2024: $44.54 million | Q2 2024: $62.26 million | Q3 2024: $92.80 million | Q1 2025: $106.45 million | Q2 2025: $99.24 million | Q3 2025: $97.22 million.
- Over the full 7 years of available data (2019 to 2025), Dyne Therapeutics, Inc.'s Research And Development Expense has grown by 3,508.1%.
- Historical annual values: Fiscal year 2025: $398.33 million | Fiscal year 2024: $281.41 million | Fiscal year 2023: $210.76 million | Fiscal year 2022: $142.76 million | Fiscal year 2021: $121.31 million | Fiscal year 2020: $45.20 million | Fiscal year 2019: $11.04 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: